Patterns and Trends of Antimicrobial Resistance of WHO Bacterial Priority Pathogens in Kenya: data from multi-site surveillance for the period 2021-2025
Based on multi-site surveillance data from 2021 to 2025, this study reveals alarming and increasing trends of antimicrobial resistance among WHO priority pathogens in Kenya, particularly highlighting high rates of carbapenem-resistant *Klebsiella pneumoniae* and methicillin-resistant *Staphylococcus aureus*, which underscores the urgent need for strengthened infection control and antimicrobial stewardship.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
In the invisible world of microscopic life, bacteria are constantly evolving. When humans use medicines designed to kill them, the strongest bacteria survive and pass on their defenses, creating strains that no longer respond to treatment. This phenomenon, known as antimicrobial resistance, turns common infections into dangerous, difficult-to-treat illnesses. For decades, scientists have worried that this process is accelerating, particularly in regions where access to advanced laboratories is limited. Without a clear picture of which bacteria are becoming resistant and to which medicines, doctors are forced to guess at treatments, often using the wrong drugs and allowing the strongest bacteria to spread further. To stop this, health officials need a precise map of the problem, showing exactly where the resistance is growing and how fast.
A team of researchers in Kenya has drawn such a map by looking at data collected from hospitals across the country over five years. They focused on a specific group of bacteria that the World Health Organization has identified as the most dangerous threats to human health. These are the "priority pathogens," a list of germs that cause the most severe infections and are most likely to become resistant to our best medicines. The researchers gathered samples from twenty different hospitals, ranging from large national centers to regional referral facilities. They looked at bacteria found in urine, blood, and the lungs of patients between 2021 and 2025. By testing these bacteria against various antibiotics, they could see which drugs still worked and which ones the bacteria had learned to ignore.
The picture that emerged is one of a rapidly changing landscape. The study found that the number of these dangerous bacteria being identified grew dramatically, more than doubling from the start of the period to the end. This increase was not necessarily because more people were getting sick, but because the surveillance system itself improved, capturing more data than ever before. The most common culprits were two types of bacteria: Escherichia coli, often found in the gut, and Klebsiella pneumoniae, which frequently causes lung and blood infections. Together, these two made up more than three-quarters of all the priority bacteria found in the study.
The resistance patterns revealed a troubling trend. For Escherichia coli and Klebsiella pneumoniae, the drugs that doctors typically rely on as a first line of defense, known as third-generation cephalosporins, were failing in the majority of cases. In fact, nearly two-thirds of the E. coli samples and almost four-fifths of the Klebsiella pneumoniae samples were resistant to these medicines. Even more concerning was the rise of resistance to a class of drugs called carbapenems, which are often considered the last resort when other antibiotics fail. The study showed that resistance to these powerful drugs in Klebsiella pneumoniae jumped from roughly 18 percent in 2021 to nearly 36 percent by 2025. This means that for a significant and growing number of patients, the final line of defense is no longer working.
The situation was equally serious for a different type of germ, a bacterium called Staphylococcus aureus, which is a common cause of skin and blood infections. The study tracked the rise of a strain known as MRSA, which is resistant to methicillin, a standard antibiotic. In 2021, about 37 percent of these bacteria were resistant, but by 2025, that number had climbed to 56 percent. This indicates that more than half of the Staphylococcus infections found in these hospitals could not be treated with the usual medicines. While the researchers did not find any cases of the bacteria becoming resistant to vancomycin, another powerful drug used as a last resort for these infections, the steady climb in resistance to other drugs is a clear warning sign.
The data also showed that these resistant bacteria were not just appearing in one type of sample. They were found in urine, blood, and respiratory specimens, suggesting they are spreading through different parts of the body and different types of infections. The researchers noted that the bacteria found in blood and lung samples were often the same ones causing trouble in urine, pointing to a widespread presence of these resistant strains throughout the healthcare system. The study also highlighted that the problem was not uniform across the country; resistance levels varied by region, with some areas showing higher rates of resistance to specific drugs than others.
Despite the grim numbers, the study offers a clear path forward. The authors emphasize that the rise in resistance is not an inevitable fate but a result of how antibiotics are used and how infections are prevented. They point out that the increase in data collection itself is a victory, proving that with better funding and training, even resource-limited settings can build strong surveillance systems. However, the data also makes it clear that current measures are not enough. The researchers call for urgent action to improve how hospitals prevent the spread of germs, to ensure that antibiotics are used only when necessary, and to develop new treatments that can fight these resistant strains. Without these steps, the effectiveness of modern medicine against bacterial infections will continue to erode, leaving patients vulnerable to diseases that were once easily cured.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.